CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia

被引：85

作者：

Kajinami, K

Brousseau, ME

Ordovas, JM

Schaefer, EJ

机构：

[1] Kanazawa Med Univ, Dept Cardiol, Uchinada, Ishikawa 9200293, Japan

[2] Tufts Univ, New England Med Ctr, Lipid Res Lab, Div Endocrinol Metab & Mol Biol, Boston, MA 02111 USA

[3] Tufts Univ, USDA, Human Nutr Res Ctr Aging, Lipid Metab Lab, Boston, MA 02111 USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2004年 / 93卷 / 01期

关键词：

D O I：

10.1016/j.amjcard.2003.08.078

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To test whether genetic variation in the CYP system may influence the statin response, a promoter (A290G) and 2 nonsynonymous polymorphisms (F189S and M445T) in the CYP3A4 gene locus were examined in 340 hypercholesterolemic patients who were treated with atorvastatin 10 mg. The A-290G variant allele Was significantly associated with higher levels of post-treatment low-density lipoprotein cholesterol, whereas the M445T variant was associated with lower levels at low-density lipoprotein cholesterol before and after treatment. (C) 2003 by Excerpta Medica, Inc.

引用

收藏

页码：104 / 107

页数：4

相关论文

共 20 条

[11] Effect of itraconazole on the pharmacokinetics of atorvastatin [J].

Kantola, T ;

Kivistö, KT ;

Neuvonen, PJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (01) :58-65

[12] Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin [J].

Mulder, AB ;

van Lijf, HJ ;

Bon, MAM ;

van den Bergh, FAJTM ;

Touw, DJ ;

Neef, C ;

Vermes, I .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (06) :546-551

[13] THE P450 SUPERFAMILY - UPDATE ON NEW SEQUENCES, GENE-MAPPING, ACCESSION NUMBERS, EARLY TRIVIAL NAMES OF ENZYMES, AND NOMENCLATURE [J].

NELSON, DR ;

KAMATAKI, T ;

WAXMAN, DJ ;

GUENGERICH, FP ;

ESTABROOK, RW ;

FEYEREISEN, R ;

GONZALEZ, FJ ;

COON, MJ ;

GUNSALUS, IC ;

GOTOH, O ;

OKUDA, K ;

NEBERT, DW .

DNA AND CELL BIOLOGY, 1993, 12 (01) :1-51

[14] Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism? [J].

Nordin, C ;

Dahl, ML ;

Eriksson, M ;

Sjoberg, S .

LANCET, 1997, 350 (9070) :29-30

[15] Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner [J].

Pedro-Botet, J ;

Schaefer, EJ ;

Bakker-Arkema, RG ;

Black, DM ;

Stein, EM ;

Corella, D ;

Ordovas, JM .

ATHEROSCLEROSIS, 2001, 158 (01) :183-193

[16] Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 [J].

Rebbeck, TR ;

Jaffe, JM ;

Walker, AH ;

Wein, AJ ;

Malkowicz, SB .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (16) :1225-1229

[17] More about: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 [J].

Rebbeck, TR .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (01) :76-76

[18] CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12:: Evidence for an allelic variant with altered catalytic activity [J].

Sata, F ;

Sapone, A ;

Elizondo, G ;

Stocker, P ;

Miller, VP ;

Zheng, W ;

Raunio, H ;

Crespi, CL ;

Gonzalez, FJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (01) :48-56

[19]

Siedlik PH, 1999, J CLIN PHARMACOL, V39, P501

[20] Genomic medicine - Inheritance and drug response. [J].

Weinshilboum, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) :529-537